Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ZG005 in patients with advanced solid tumors
CTR20251131Phase 2Active
- Sponsor
- Zelgen
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nilvanstomig in Nonhematologic neoplasms, sponsored by Zelgen. Started Jun 2025; status: active.
02
Drugs
nilvanstomig
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251131.